Pharmacodynamics and pharmacokinetics of BAY x 7195 aerosol, a new and selective receptor antagonist of cysteinyl-leukotrienes, in normal volunteers

British Journal of Clinical Pharmacology

Volumn 42, Issue 2, 1996, Pages 171-178

  Wensing, G ^a   Heinig, R ^a   Kuhlmann, J ^a  

^a BAYER AG   (Germany)

Author keywords

Bronchial challenge; Leukotriene D4; Powder aerosol

Indexed keywords

4 (4 CARBOXYPHENYLTHIO) 7 [4 (4 PHENOXYBUTOXY)PHENYL] 5 HEPTENOIC ACID; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; AEROSOL; AIRWAY CONDUCTANCE; AREA UNDER THE CURVE; ARTICLE; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; LUNG FUNCTION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; TABLET; VOLUNTEER;

EID: 0030055797     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.03505.x     Document Type: Article

References (32)

1. Burney PGJ, Papacosta AO, Withey CH, Colley JRT, Holland WW. Hospital admission rates and prevalence of asthma symptoms in 20 local authority districts. Thorax 1991; 46: 574-579.
2. Keeley DJ, Neill P, Gallivan S. Comparison of the prevalence of reversible airways obstruction in rural and urban Zimbabwean children. Thorax 1991; 46: 549-553.
3. Dahlen SR, Hedquist P, Hammarström S, Samuelson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288: 484-486.
4. Woodward DF, Weichman BM, Gill CA, Wasserman MA. The effect of synthetic leukotrienes on tracheal microvascular permeability. Prostaglandins 1983; 25: 131-142.
5. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126: 449-451.
6. Lam S, Chan H, LeRiche JC. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988; 81: 711-717.
7. Taylor GW, Taylor I, Black P, et al. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; i: 584-588.
8. 4 in patients with asthma. Am Rev Respir Dis 1991; 143: 1322-1328.
9. Drazen JM, O'Brien J, Sparrow D, et al. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992; 146: 104-108.
10. 4 in humans. Am Rev Respir Dis 1985; 131: 368-372.
11. 4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986; 315: 480-484.
12. 4 in subjects with asthma and normal subjects. J Allergy Clin Immunol 1988; 82: 654-660.
13. Abram TS, Böshagen H, Butler JE, et al. A new structural analogue antagonist of peptide-leukotrienes. The discovery of BAY x 7195. Bioorganic and Medicinal Chemistry Letters 1993; 8: 1517-1522.
14. Abram TS, Cuthbert NJ, Francis HP, Gardiner PJ, Norman P, Taylor WA. Pharmacological profile of BAY x 7195, a structural antagonist of cysteinylleukotrienes. Am Rev Respir Dis 1993; 147 (Supplement): A179.
15. 4-induced bronchoconstriction in normal volunteers. Eur J Clin Pharmacol 1994; 47: 227-230.
16. 4 antagonist in human plasma by high-performance liquid chromatography with post-column photo derivatisation and fluorescence detection. J Chromatogr B 1995; 667: 137-147.
17. Magnussen H, Boerger S, Templin K, Baunack AR. Effects of a thromboxane receptor antagonist (BAY u 3405) on prostaglandin D2 and exercise-induced asthma. J Allergy Clin Immunol 1988; 81: 919-934.
18. Adamus WS, Heuer H, Meade CJ, Schilling JC. Inhibitory effects of the new PAF receptor antagonist WEB 2086 on pharmacologic changes induced by PAF inhalation in human beings. Clin Pharmacol Ther 1990; 47: 456-462.
19. 4-receptor antagonist ICI 204, 219. Am Rev Respir Dis 1990; 141: 988-992.
20. 4 in normal subjects. Comparison and interaction with methacholine. Am Rev Respir Dis 1987; 136: 979-984.
21. Weiss JW, Drazen JM, McFadden ER, et al. Airway constriction in normal humans produced by inhalation of leukotriene D. JAMA 1983; 249: 2814-2817.
22. 4 in normal subjects. Am Rev Respir Dis 1986; 133: 1127-1132.
23. 4 inhalation challenge in asthmatics. Allergy 1991; 46: 355-361.
24. 4 induced bronchoconstriction in the human. Am Rev Resp Dis 1991; 144: 617-621.
25. Heinig R, Schäfer HG, Wensing G, Kuhlmann J. Pharmacokinetics, safety and tolerability of the orally administered receptor antagonist of cysteinylleukotrienes BAY x 7195 in single dose escalation studies. Int J Clin Pharmacol Ther 1995; 33: 573-579.
26. 4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993; 147: 1431-1435.
27. 4 and histamine induced bronchoconstriction in normal man. Br J Clin Pharmacol 1988; 26: 677-678.
28. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of the cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337: 690-694.
29. Friedman BS, Bel EH, Buntinx A, et al. Oral leukotriene inhibitor (MK 886) blocks allergen induced airway responses. Am Rev Respir Dis 1993; 147: 839-844.
30. 4 induced bronchoconstriction in subjects with asthma: A concentration-effect study of ICI 204, 219. Clin Pharmacol Ther 1993; 54: 430-436.
31. Specter SL, Smith LJ, Glass M, and the accolate asthma trialists group. Effects of six weeks of therapy with oral doses of ICI 204, 219, a leukotriene-D4 receptor antagonist, in subjects with bronchial asthma. Am J Resp Crit Care Med 1994; 150: 618-623.
32. Spector S, Miller CJ, Glass M. 13-week dose response study with AccolateTM (zafirlukast) in patients with mild to moderate asthma. Resp Crit Care Med 1995, 151: A379.